Cagrilintide

China [CN]

Cagrilintide is an investigational long-acting amylin analogue developed by Novo Nordisk for weight management in people with obesity or overweight, and is also being studied for type 2 diabetes and chronic kidney disease. It works by mimicking the naturally occurring satiety hormone amylin, which helps regulate food intake, slow gastric emptying, and reduce appetite